Drug intelligence / Profile preview

Enerzad Extra

Development stage: Unknown
Lead developer: ARAX Pharmaceutical Industries
Modality: Small Molecules
Administration: Oral

Overview

Enerzad Extra is an oral film-coated tablet developed and marketed by ARAX Pharmaceutical Industries in Egypt. It is formulated as a combination of L-arginine and L-aspartate, designed to support reproductive health and address infertility in both men and women. L-arginine serves as a precursor for nitric oxide synthesis, which promotes vasodilation and improves blood flow to reproductive organs, thereby supporting sperm quality, count, and motility, as well as ovum health and implantation. L-aspartate is included to support metabolic energy and potentially modulate testosterone levels. The product is marketed as a pharmaceutical supplement and is available in packs of 30 tablets.

Brand names: Enerzad Extra
Other names: Enerzad Extra 30 film coated tablets

Targets

NOS1 (nNOS)

Beyond the preview

Go deeper on Enerzad Extra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enerzad Extra.

Explore the full profile